SlideShare une entreprise Scribd logo
1  sur  17
Télécharger pour lire hors ligne
Stockholm, Sweden | June 2014
COTI-2 | Reactivating Mutant P53
FORWARD LOOKING STATEMENTS
When used anywhere in this presentation, the words expects, believes, anticipates,
estimates, and similar expressions are intended to identify forward-looking
statements. Forward-looking statements herein may include statements addressing
future financial and operating results for Critical Outcome Technologies Inc., (COTI).
COTI has based these forward-looking statements on its current expectations about
future events. Such statements are subject to risks and uncertainties including, but
not limited to, the successful implementation of COTI’s strategic plans, the
acceptance of new products, the obsolescence of existing products, the resolution
of existing and potential future patent issues, additional competition, changes in
economic conditions, and other risks described in documents COTI has filed with
the Toronto Stock Exchange and Ontario Securities Commission.
All forward-looking statements in this document are qualified entirely by the
cautionary statements included in this document and such filings. These risks and
uncertainties could cause actual results to differ materially from results expressed
or implied by forward-looking statements contained in this document. These
forward-looking statements speak only as of the date of this document.
2
3
COTI-2 INTRODUCTION
• COTI-2 is a small molecule with a novel mechanism of action, discovered by our
CHEMSAS process
– Originally thought to be an AKT modulator/inhibitor
• It is a 3rd generation thiosemicarbazone engineered for low toxicity and easily
synthesized in 3 steps
• It demonstrates strong in vitro and in vivo efficacy
• COTI-2 is effective in cancer cells/tumors with many common p53 mutations
N
N
N
H
S
N
N
N
3rd Generation
Thiosemicarbazone
4
COTI-2 IC50 STRONGLY CORRELATED WITH p53 STATUS
• TP53 is the most frequently mutated gene in human cancer with mutation
frequencies ranging from 38% to 96%1
– Most frequent mutations occur in 6 “hotspot” codons2
• 23 cell line were evaluated for the relationship between their COTI-2 IC50 and p53
“hotspot” mutational status (amino acid residues 175, 248, and 273)
– COTI-2’s efficacy was strongly associated with the presence of p53 “hotspot” mutations
(Fisher exact, p = 0.0045)
1Freed-Pastor WA & Prives C (2012) Genes Dev. 26: 1268-1286.
2Yu X et al (2012) Cancer Cell, 21: 614-625..
LOW IC50
(< 250 nM)
HIGH IC50
(≥ 250 nM)
TOTAL
Hotspot p53 Mutations
(175, 248, 273)
13 0 13
WT p53 5* 5 10
TOTAL 18 5 23
Common p53 Gene Mutations
COTI-2 Efficacy Associated with p53 Hotspot Mutations
~28% of human cancers
* These cell lines also have mutations in p73 or the
PI3K/AKT/mTOR pathway
-10.00
-9.00
-8.00
-7.00
-6.00
-5.00
-4.00
-3.00
5
COTI-2 IC50 DISTRIBUTION IN HUMAN CANCER CELL LINES
• COTI-2 IC50 distribution in various human cancer cell lines as illustrated by a
waterfall chart shows 3 major groups of cell lines
Normal Human WBCs
MCF7 and NCI-H460:
WT p53 + PIK3CA mutation
U87MG:
WT p53 + PTEN mutation
NCI-H292:
WT p53 + p73 mutation
HCT116:
WT p53 + PIK3CA mutation
PANC-1:
p53 (R273H)
OVCAR-3 PK/PD xenograft
p53 (R248G)
GROUP 1 GROUP 2 GROUP 3
p53 = Wild-type
Mutants = p53 Wild-type AND p73, PI3K, or PTEN Mutant
p53 = Null Mutants
p53 = Hotspot & Non-Hotspot Mutants
6
COTI-2 INDUCES A CONFORMATIONAL CHANGE IN MUTANT P53
• COTI-2 induces a ‘wild-type-like’ conformational change in mutant p53R175H in TOV-
112D ovarian cancer cell line
• Data also suggests a mutant p53 conformational change also occurs in PANC-1
(p53R273H) pancreatic and OVCAR-3 (p53R248Q) ovarian cancer cell lines
Experimental Design
• Fluorescently labeled antibodies specific for wild-type & mutant p53 used to assess cells grown in the presence/absence of COTI-2
• PAB1620-stained cells show wild-type p53 and PAB240-stained cells show mutant p53
• Cy3 refers to the fluorescent signal emitted by the fluor attached to the antibodies
• DAPI-staining indicates intact nuclei and provides the assurance that the cells are intact
7
COTI-2 HAS NO AFFECT ON P53 WILD-TYPE CONFORMATIONAL STATUS
• COTI-2 has no affect on the wild-type p53 conformation as demonstrated by the
H460 NSCLC cell line, which was used as a control
Experimental Design
• Fluorescently labeled antibodies specific for wild-type & mutant p53 used to assess cells grown in the presence/absence of COTI-2
• PAB1620-stained cells show wild-type p53 and PAB240-stained cells show mutant p53
• Cy3 refers to the fluorescent signal emitted by the fluor attached to the antibodies
• DAPI-staining indicates intact nuclei and provides the assurance that the cells are intact
8
COTI-2 TARGETS P53 MUTANT PROTEIN
• COTI-2 significantly reduces p53 mutant protein levels and significantly increases
wild-type p53 protein levels in TOV-112D cells likely by inducing a conformational
change
• COTI-2 has no significant effect on p53 protein levels in the H460 cell line, which
do not carry the mutant p53 protein
• (*) Significant difference in p53 protein levels between COTI-2 treated and untreated cells (control)
Mutant p53 Levels in the Presence/Absence of COTI-2 Wild-type p53 Levels in the Presence/Absence of COTI-2
0
20
40
60
80
100
120
TOV-112D H460
MeanFluorescenceIntensity
(ArbitraryUnits)
Cell Line
Control
COTI-2
*
0
20
40
60
80
100
TOV-112D H460
MeanFluorescenceIntensity
(ArbitraryUnits)
Cell Line
Control
COTI-2
*
9
COTI-2 AFFECTS A WIDE RANGE OF P53 MUTATIONS
• COTI-2 inhibited a wide range of p53 mutations at concentrations  1.0 M
– Fifteen p53 mutations were inhibited by COTI-2 (shown below in red)
– The p53 mutations correspond to those most frequently occurring in various human
cancers
Experimental Design
• HCT116 p53 (-/-)
constructs were
transfected with
plasmids bearing various
p53 mutant genes
• Each transfectant was
exposed to 1.0 M of
COTI-2 for 72 hrs and
viability assessed
• The cell viability was
determined using the
CellTiter-Blue® Assay
Unlike other p53 targeted drugs in development COTI-2 targets a wider range of p53 mutations
N C
S
G C
H L
S C R W G Q C G S R Y
V D A L P W L H P S F
R175 C275R273R248G245Y220
10
COTI-2 REACTIVATES MUTANT P53
• COTI-2 reactivates the tumor suppressor properties of p53 as demonstrated by the
induction of p21, which is a p53-dependent gene
– COTI-2 induces p21 at 3 and 12 h post-exposure in both the HCT116 p53 (R175H) and
(G245C) mutant constructs
– No difference in p21 protein levels were observed in the HCT116 p53 (-/-) construct
Experimental Design
• Cells were incubated with/without COTI-2 and protein extractions performed at 2 and 12 h post-incubation
• Protein levels were detected via western blots using p53, p21, and Erk2 specific antibodies
1 2 3 4
HCT116 p53 (R175H) HCT116 p53 (G245C)HCT116 p53 (-/-)
3h
- +
12h
- +
1 2 3 4
p53
p21
Erk2
COTI-2
3h
- +
12h
- +
3h
- +
12h
- +
1 2 3 4
COTI-2 REACTIVATES MUTANT P53 THROUGH ZINC CHELATION
• 8 genes involved in metal ion chelation up-
regulated by COTI-2 (p<0.01)
• Iron chelation unlikely to be significant effect
• Pre-treatment of p53 mutant cell lines with TPEN
markedly reduces COTI-2 effectiveness
• COTI-2 increases intracellular zinc concentrations
• Experiments are ongoing to better understand
the role of zinc in COTI-2 effectiveness
11
12
CONFIRMATION OF P53-DEPENDENT MOA
• Gordon Mills, MD., PhD., Chair of the Department of Systems Biology and the Co-
Director of the Khalifa Institute for Personalized Cancer Therapy at The University
of Texas MD Anderson Cancer Center in Houston, Texas conducted a number of
cell-based experiments to further elucidate the activity of COTI-2 on various p53
mutations
• Dr. Mills’ research confirmed
– COTI-2 is most active in mutant p53 tumors
– COTI-2’s activity in many specific p53 mutations is striking
– COTI-2’s activity can be augmented by the presence of mutations in the AKT signaling
pathway
– Results of in vitro/in vivo studies in combination with the potential MOA warrant further
clinical development
“These results are encouraging given the central importance of p53 gene mutations in many cancers”
Dr. Gordon Mills, MD Anderson Cancer Center
13
COTI-2 INDUCED NO SIGNIFICANT RESISTANCE
• COTI-2 induced no significant resistance through 5 generations in both cell lines
• Both Cisplatin and Placlitaxel induce significant increases in IC50 after first
generation of selection compared with COTI-2
• COTI-2 induced a statistically significant decrease in IC50’s (i.e., Collateral
Sensitivity)
0
0.5
1
1.5
2
2.5
3
Parental
cells
Round1
selection
Round2
selection
Round3
selection
Round4
selection
COTI-2
COTI-219
Cisplatin
Paclitaxel
0
1
2
3
4
5
6
7
8
Parental
cells
Round1
selection
Round2
selection
Round3
selection
Round4
selection
COTI-2
COTI-219
Cisplatin
Paclitaxel
IC50Ratio
DMS153 SCLC SHP77 SCLC
IC50Ratio
14
COTI-2 PRODUCED SIGNIFICANT TGI AS A SINGLE AGENT
• COTI-2 administered PO produced a significant tumor growth inhibition as a single
agent in the OVCAR-3 ovarian cancer tumor model
Experimental Design
• OVCAR3 human tumor cells
inoculated subcutaneously in
the right and left flanks of
female athymic mice (NIH III
nu/nu), allowed to grow up to
75 to 100 mm3
• Groups of 12 mice each were
dosed PO with COTI-2 in
phosphate citrate buffer (75 or
100 mg/kg) with a schedule of
5X per week until study end
• Tumor volumes were graphed
as means (SE) and significant
difference between groups was
determined using Student’s T-
test (p<0.05)
• (*) Tumors significantly reduced by COTI-2 in all treatment groups relative to vehicle control
0
50
100
150
200
250
0 5 9 16 23 30 37 44 51 61
TumorVolume(mm3)
Study Day
Group 4 = Vehicle PO
Group 5 = COTI-2 75mg/kg PO
Group 6 = COTI-2 100mg/kg PO
Effect of Treatment on Tumor Volume
*
*
*
* *
*
* *
* *
* *
15
SUMMARY
• COTI-2 is a small molecule with a novel mechanism of action, discovered by our
CHEMSAS process
• MOA
– COTI-2 appears to restore wild-type like functional activity to a wide range of p53
mutants through zinc chelation
• In vitro efficacy
– COTI-2 demonstrates nanomolar activity in multiple human cancer cell lines
– COTI-2 did not induce cross-resistance compared to cisplatin and paclitaxel
• In vivo efficacy
– When administered PO, COTI-2 induced significant tumor growth inhibition (85.5%) in an
ovarian tumor xenograft model without any overt toxicity in mice
• Clinical development strategy
– IND filing is planned for mid-2014
– Gynecological (ovarian, endometrial, and cervical) cancer patients failing 1st line therapy
• FDA Orphan status granted June, 2014 “for the treatment of ovarian cancer”
16
COTI-2 NEGATIVELY MODULATES THE PI3K/AKT/MTOR PATHWAY
1Hennessy BT et al (2005) Nature Rev Drug Discov, 4: 988-1004.
• This pathway has been implicated in cancer and is involved in cell proliferation,
survival, motility and morphology1
• COTI-2 negatively modulates the PI3K/AKT/mTOR pathway
– COTI-2 directly inhibits PI3K via the upregulation of PIK3IP1
– Increased/restored p53 function stimulates PTEN activity
– Increased/restored p53 function leads to AKT protein degradation
PI3K
AKT
MDM2
p53
FOXO1 BAD GSK3B mTOR S6KCASP-9
RTK
Apoptosis
Cell cycle regulation
DNA repair
Apoptosis Cell cycle regulation Growth
Translation
PIK3IP1
PTEN
COTI-2 Upregulates PIK3IP1
Study # COTI-07-101
Follow @CriticalOutcome on Twitter
COTI-2 | Reactivating Mutant P53

Contenu connexe

Tendances

Agrobacterium mediated gene transfer in plants.
Agrobacterium mediated gene transfer in plants.Agrobacterium mediated gene transfer in plants.
Agrobacterium mediated gene transfer in plants.ICHHA PURAK
 
Knockdown of lncRNAs: exploring RNAi and antisense oligo methods
Knockdown of lncRNAs: exploring RNAi and antisense oligo methodsKnockdown of lncRNAs: exploring RNAi and antisense oligo methods
Knockdown of lncRNAs: exploring RNAi and antisense oligo methodsIntegrated DNA Technologies
 
Tilling &amp; eco tilling indrajay delvadiya
Tilling &amp; eco tilling indrajay delvadiyaTilling &amp; eco tilling indrajay delvadiya
Tilling &amp; eco tilling indrajay delvadiyaDr. Indrajay R. Delvadiya
 
Cytogenetic stocks in in plant breeding
Cytogenetic stocks in in plant breedingCytogenetic stocks in in plant breeding
Cytogenetic stocks in in plant breedingmanjeet singh
 
Genetic diversity analysis
Genetic diversity analysisGenetic diversity analysis
Genetic diversity analysisAKHISHA P. A.
 
Diversity Array technology
Diversity Array technologyDiversity Array technology
Diversity Array technologyManjesh Saakre
 
Preparatiion of competent cells & Transformation Practical
Preparatiion of competent cells & Transformation Practical Preparatiion of competent cells & Transformation Practical
Preparatiion of competent cells & Transformation Practical Sabahat Ali
 
Genome Editing in Fruit Crops
Genome Editing in Fruit CropsGenome Editing in Fruit Crops
Genome Editing in Fruit Crops_mk_ saini
 
Double haploid production
Double haploid production Double haploid production
Double haploid production Kalpataru Nanda
 
Presentation on Foreground and Background Selection using Marker Assisted Sel...
Presentation on Foreground and Background Selection using Marker Assisted Sel...Presentation on Foreground and Background Selection using Marker Assisted Sel...
Presentation on Foreground and Background Selection using Marker Assisted Sel...Dr. Kaushik Kumar Panigrahi
 
Forward and reverse genetics
Forward and reverse geneticsForward and reverse genetics
Forward and reverse geneticsSachin Ekatpure
 
production of double haploid plants
 production of double haploid plants production of double haploid plants
production of double haploid plantsvruddhi desai
 
Reeta yadav. roll no. 02. transposable element in eukaryotes.
Reeta yadav. roll no. 02. transposable element in eukaryotes.Reeta yadav. roll no. 02. transposable element in eukaryotes.
Reeta yadav. roll no. 02. transposable element in eukaryotes.Manisha Jangra
 
Plant disease management tissue culture techniques
Plant disease management  tissue culture techniquesPlant disease management  tissue culture techniques
Plant disease management tissue culture techniquessubhashB10
 
Gene Expression Analysis by Real Time PCR
Gene Expression Analysis by Real Time PCRGene Expression Analysis by Real Time PCR
Gene Expression Analysis by Real Time PCRSuresh Antre
 

Tendances (20)

Lecture 7 gwas full
Lecture 7 gwas fullLecture 7 gwas full
Lecture 7 gwas full
 
cisgenesis and intragenesis
cisgenesis and intragenesiscisgenesis and intragenesis
cisgenesis and intragenesis
 
CISGENICS
CISGENICSCISGENICS
CISGENICS
 
Agrobacterium mediated gene transfer in plants.
Agrobacterium mediated gene transfer in plants.Agrobacterium mediated gene transfer in plants.
Agrobacterium mediated gene transfer in plants.
 
Knockdown of lncRNAs: exploring RNAi and antisense oligo methods
Knockdown of lncRNAs: exploring RNAi and antisense oligo methodsKnockdown of lncRNAs: exploring RNAi and antisense oligo methods
Knockdown of lncRNAs: exploring RNAi and antisense oligo methods
 
Tilling &amp; eco tilling indrajay delvadiya
Tilling &amp; eco tilling indrajay delvadiyaTilling &amp; eco tilling indrajay delvadiya
Tilling &amp; eco tilling indrajay delvadiya
 
Cytogenetic stocks in in plant breeding
Cytogenetic stocks in in plant breedingCytogenetic stocks in in plant breeding
Cytogenetic stocks in in plant breeding
 
Genetic diversity analysis
Genetic diversity analysisGenetic diversity analysis
Genetic diversity analysis
 
Diversity Array technology
Diversity Array technologyDiversity Array technology
Diversity Array technology
 
Preparatiion of competent cells & Transformation Practical
Preparatiion of competent cells & Transformation Practical Preparatiion of competent cells & Transformation Practical
Preparatiion of competent cells & Transformation Practical
 
Genome Editing in Fruit Crops
Genome Editing in Fruit CropsGenome Editing in Fruit Crops
Genome Editing in Fruit Crops
 
Double haploid production
Double haploid production Double haploid production
Double haploid production
 
Presentation on Foreground and Background Selection using Marker Assisted Sel...
Presentation on Foreground and Background Selection using Marker Assisted Sel...Presentation on Foreground and Background Selection using Marker Assisted Sel...
Presentation on Foreground and Background Selection using Marker Assisted Sel...
 
Forward and reverse genetics
Forward and reverse geneticsForward and reverse genetics
Forward and reverse genetics
 
production of double haploid plants
 production of double haploid plants production of double haploid plants
production of double haploid plants
 
Reeta yadav. roll no. 02. transposable element in eukaryotes.
Reeta yadav. roll no. 02. transposable element in eukaryotes.Reeta yadav. roll no. 02. transposable element in eukaryotes.
Reeta yadav. roll no. 02. transposable element in eukaryotes.
 
Plant disease management tissue culture techniques
Plant disease management  tissue culture techniquesPlant disease management  tissue culture techniques
Plant disease management tissue culture techniques
 
Gene Expression Analysis by Real Time PCR
Gene Expression Analysis by Real Time PCRGene Expression Analysis by Real Time PCR
Gene Expression Analysis by Real Time PCR
 
CRISPR Cas 9.pptx
CRISPR Cas 9.pptxCRISPR Cas 9.pptx
CRISPR Cas 9.pptx
 
Association mapping
Association mappingAssociation mapping
Association mapping
 

En vedette

Activation of p53 mediated glycolytic inhibition-oxidative stressapoptosis pa...
Activation of p53 mediated glycolytic inhibition-oxidative stressapoptosis pa...Activation of p53 mediated glycolytic inhibition-oxidative stressapoptosis pa...
Activation of p53 mediated glycolytic inhibition-oxidative stressapoptosis pa...rkkoiri
 
Cancer P53 By Swati Seervi
Cancer P53 By Swati SeerviCancer P53 By Swati Seervi
Cancer P53 By Swati Seerviswati seervi
 
More than just a potential BREAKTHROUGH treatment for many cancers
More than just a potential BREAKTHROUGH treatment for many cancersMore than just a potential BREAKTHROUGH treatment for many cancers
More than just a potential BREAKTHROUGH treatment for many cancersCritical Outcome Technologies Inc.
 
G Protein Coupled Receptors (GPCRs) and Cancer
G Protein Coupled Receptors (GPCRs) and CancerG Protein Coupled Receptors (GPCRs) and Cancer
G Protein Coupled Receptors (GPCRs) and CancerDayananda Salam
 
P53 Tumor Suppressor Gene: Understanding P53 Based Dietary Anti Cancer Thera...
P53  Tumor Suppressor Gene: Understanding P53 Based Dietary Anti Cancer Thera...P53  Tumor Suppressor Gene: Understanding P53 Based Dietary Anti Cancer Thera...
P53 Tumor Suppressor Gene: Understanding P53 Based Dietary Anti Cancer Thera...Sheldon Stein
 
G protein coupled receptor
G protein coupled receptorG protein coupled receptor
G protein coupled receptorFardan Qadeer
 

En vedette (12)

Business and Scientific Update
Business and Scientific UpdateBusiness and Scientific Update
Business and Scientific Update
 
Critical Outcome investor presentation - November 2015
Critical Outcome investor presentation - November 2015Critical Outcome investor presentation - November 2015
Critical Outcome investor presentation - November 2015
 
Critical Outcome Technologies - May 2014
Critical Outcome Technologies - May 2014Critical Outcome Technologies - May 2014
Critical Outcome Technologies - May 2014
 
Activation of p53 mediated glycolytic inhibition-oxidative stressapoptosis pa...
Activation of p53 mediated glycolytic inhibition-oxidative stressapoptosis pa...Activation of p53 mediated glycolytic inhibition-oxidative stressapoptosis pa...
Activation of p53 mediated glycolytic inhibition-oxidative stressapoptosis pa...
 
Cancer P53 By Swati Seervi
Cancer P53 By Swati SeerviCancer P53 By Swati Seervi
Cancer P53 By Swati Seervi
 
Introducing ROSALIND
Introducing ROSALINDIntroducing ROSALIND
Introducing ROSALIND
 
More than just a potential BREAKTHROUGH treatment for many cancers
More than just a potential BREAKTHROUGH treatment for many cancersMore than just a potential BREAKTHROUGH treatment for many cancers
More than just a potential BREAKTHROUGH treatment for many cancers
 
G Protein Coupled Receptors (GPCRs) and Cancer
G Protein Coupled Receptors (GPCRs) and CancerG Protein Coupled Receptors (GPCRs) and Cancer
G Protein Coupled Receptors (GPCRs) and Cancer
 
P53 Tumor Suppressor Gene: Understanding P53 Based Dietary Anti Cancer Thera...
P53  Tumor Suppressor Gene: Understanding P53 Based Dietary Anti Cancer Thera...P53  Tumor Suppressor Gene: Understanding P53 Based Dietary Anti Cancer Thera...
P53 Tumor Suppressor Gene: Understanding P53 Based Dietary Anti Cancer Thera...
 
G protein coupled receptor
G protein coupled receptorG protein coupled receptor
G protein coupled receptor
 
Genomics & Proteomics Based Drug Discovery
Genomics & Proteomics Based Drug DiscoveryGenomics & Proteomics Based Drug Discovery
Genomics & Proteomics Based Drug Discovery
 
G- Protein Coupled Receptors
G- Protein Coupled ReceptorsG- Protein Coupled Receptors
G- Protein Coupled Receptors
 

Similaire à COTI-2 | Reactivating Mutant p53

ZP Summer 2015 Poster
ZP Summer 2015 PosterZP Summer 2015 Poster
ZP Summer 2015 PosterZaw Phyo
 
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...AvactaLifeSciences
 
Cupid Peptides presentation wjr
Cupid Peptides presentation wjrCupid Peptides presentation wjr
Cupid Peptides presentation wjrCupid Peptides
 
Provenge (Sipuleucel T)
Provenge (Sipuleucel T)Provenge (Sipuleucel T)
Provenge (Sipuleucel T)Cytokinine
 
Investor Call
Investor CallInvestor Call
Investor Callmerckir
 
Medical review of medolife’s escozine tm technology in pre clinical &amp; cli...
Medical review of medolife’s escozine tm technology in pre clinical &amp; cli...Medical review of medolife’s escozine tm technology in pre clinical &amp; cli...
Medical review of medolife’s escozine tm technology in pre clinical &amp; cli...PetLife Pharmaceuticals Inc
 
ACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIAACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIAflasco_org
 
Provenge (sipuleucel t)
Provenge (sipuleucel t)Provenge (sipuleucel t)
Provenge (sipuleucel t)Vinblast
 
FLT3 INHIBITORS
FLT3 INHIBITORSFLT3 INHIBITORS
FLT3 INHIBITORSspa718
 
Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides coolesanum
 
Antibody-Producing Cell Lines Development
Antibody-Producing Cell Lines DevelopmentAntibody-Producing Cell Lines Development
Antibody-Producing Cell Lines Developmentcreativebiogene1
 
Rabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_ForumRabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_ForumEAFO1
 
Efficacy Studies and PK/PD of PROTAC Drugs In Vitro &Vivo
Efficacy Studies and PK/PD of PROTAC Drugs In Vitro &VivoEfficacy Studies and PK/PD of PROTAC Drugs In Vitro &Vivo
Efficacy Studies and PK/PD of PROTAC Drugs In Vitro &Vivomedicilonz
 
MCO 2011 - Slide 20 - R.A. Stahel - Spotlight session - New drugs in oncogeni...
MCO 2011 - Slide 20 - R.A. Stahel - Spotlight session - New drugs in oncogeni...MCO 2011 - Slide 20 - R.A. Stahel - Spotlight session - New drugs in oncogeni...
MCO 2011 - Slide 20 - R.A. Stahel - Spotlight session - New drugs in oncogeni...European School of Oncology
 
Eradicating diseases (genome)
Eradicating diseases (genome)Eradicating diseases (genome)
Eradicating diseases (genome)Utkarsh Verma
 

Similaire à COTI-2 | Reactivating Mutant p53 (20)

2016 Annual General & Special Meeting of Shareholders
2016 Annual General & Special Meeting of Shareholders2016 Annual General & Special Meeting of Shareholders
2016 Annual General & Special Meeting of Shareholders
 
COTI-2 Fact Sheet
COTI-2 Fact SheetCOTI-2 Fact Sheet
COTI-2 Fact Sheet
 
ZP Summer 2015 Poster
ZP Summer 2015 PosterZP Summer 2015 Poster
ZP Summer 2015 Poster
 
P53 poster
P53 posterP53 poster
P53 poster
 
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
Avacta Life Sciences Affimers Presentation Global Protein Engineering Summit ...
 
Cupid Peptides presentation wjr
Cupid Peptides presentation wjrCupid Peptides presentation wjr
Cupid Peptides presentation wjr
 
Provenge (Sipuleucel T)
Provenge (Sipuleucel T)Provenge (Sipuleucel T)
Provenge (Sipuleucel T)
 
Investor Call
Investor CallInvestor Call
Investor Call
 
Medical review of medolife’s escozine tm technology in pre clinical &amp; cli...
Medical review of medolife’s escozine tm technology in pre clinical &amp; cli...Medical review of medolife’s escozine tm technology in pre clinical &amp; cli...
Medical review of medolife’s escozine tm technology in pre clinical &amp; cli...
 
ACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIAACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIA
 
Provenge (sipuleucel t)
Provenge (sipuleucel t)Provenge (sipuleucel t)
Provenge (sipuleucel t)
 
FLT3 INHIBITORS
FLT3 INHIBITORSFLT3 INHIBITORS
FLT3 INHIBITORS
 
Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides Crizotinib a8081001 asco 2010 slides
Crizotinib a8081001 asco 2010 slides
 
Antibody-Producing Cell Lines Development
Antibody-Producing Cell Lines DevelopmentAntibody-Producing Cell Lines Development
Antibody-Producing Cell Lines Development
 
predictive marker8_27
predictive marker8_27predictive marker8_27
predictive marker8_27
 
Rabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_ForumRabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_Forum
 
Efficacy Studies and PK/PD of PROTAC Drugs In Vitro &Vivo
Efficacy Studies and PK/PD of PROTAC Drugs In Vitro &VivoEfficacy Studies and PK/PD of PROTAC Drugs In Vitro &Vivo
Efficacy Studies and PK/PD of PROTAC Drugs In Vitro &Vivo
 
MCO 2011 - Slide 20 - R.A. Stahel - Spotlight session - New drugs in oncogeni...
MCO 2011 - Slide 20 - R.A. Stahel - Spotlight session - New drugs in oncogeni...MCO 2011 - Slide 20 - R.A. Stahel - Spotlight session - New drugs in oncogeni...
MCO 2011 - Slide 20 - R.A. Stahel - Spotlight session - New drugs in oncogeni...
 
Eradicating diseases (genome)
Eradicating diseases (genome)Eradicating diseases (genome)
Eradicating diseases (genome)
 
Amphiphilic nanocarriers
Amphiphilic nanocarriersAmphiphilic nanocarriers
Amphiphilic nanocarriers
 

Plus de Critical Outcome Technologies Inc.

Critical Outcome Technologies - Investor Presentation - June 2013
Critical Outcome Technologies - Investor Presentation - June 2013Critical Outcome Technologies - Investor Presentation - June 2013
Critical Outcome Technologies - Investor Presentation - June 2013Critical Outcome Technologies Inc.
 

Plus de Critical Outcome Technologies Inc. (14)

2017 Annual General & Special Meeting of Shareholders
2017 Annual General & Special Meeting of Shareholders2017 Annual General & Special Meeting of Shareholders
2017 Annual General & Special Meeting of Shareholders
 
COTI Corporate Presentation at Cantech 2017
COTI Corporate Presentation at Cantech 2017COTI Corporate Presentation at Cantech 2017
COTI Corporate Presentation at Cantech 2017
 
COTI Overview
COTI OverviewCOTI Overview
COTI Overview
 
Small-Cap Stars
Small-Cap StarsSmall-Cap Stars
Small-Cap Stars
 
Pathway to the clinic and beyond
Pathway to the clinic and beyondPathway to the clinic and beyond
Pathway to the clinic and beyond
 
A promising advance for many cancers
A promising advance for many cancersA promising advance for many cancers
A promising advance for many cancers
 
Critical Outcome Technologies at the BIO Investor Forum 2014
Critical Outcome Technologies at the BIO Investor Forum 2014Critical Outcome Technologies at the BIO Investor Forum 2014
Critical Outcome Technologies at the BIO Investor Forum 2014
 
Critical Outcome - September 2014
Critical Outcome - September 2014Critical Outcome - September 2014
Critical Outcome - September 2014
 
Introducing ROSALIND
Introducing ROSALINDIntroducing ROSALIND
Introducing ROSALIND
 
Critical Outcome Investor Presentation - March 2014
Critical Outcome Investor Presentation - March 2014Critical Outcome Investor Presentation - March 2014
Critical Outcome Investor Presentation - March 2014
 
Critical Outcome - Investor Presentation - January 2014
Critical Outcome - Investor Presentation - January 2014Critical Outcome - Investor Presentation - January 2014
Critical Outcome - Investor Presentation - January 2014
 
Critical Outcome Technologies Business & Scientific Updates
Critical Outcome Technologies Business & Scientific UpdatesCritical Outcome Technologies Business & Scientific Updates
Critical Outcome Technologies Business & Scientific Updates
 
Critical Outcome BIO Investor Forum
Critical Outcome BIO Investor ForumCritical Outcome BIO Investor Forum
Critical Outcome BIO Investor Forum
 
Critical Outcome Technologies - Investor Presentation - June 2013
Critical Outcome Technologies - Investor Presentation - June 2013Critical Outcome Technologies - Investor Presentation - June 2013
Critical Outcome Technologies - Investor Presentation - June 2013
 

Dernier

MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxLikeways
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisNilofarRasheed1
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxsumanchaulagain3
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 

Dernier (20)

MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid Arthritis
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptx
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 

COTI-2 | Reactivating Mutant p53

  • 1. Stockholm, Sweden | June 2014 COTI-2 | Reactivating Mutant P53
  • 2. FORWARD LOOKING STATEMENTS When used anywhere in this presentation, the words expects, believes, anticipates, estimates, and similar expressions are intended to identify forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operating results for Critical Outcome Technologies Inc., (COTI). COTI has based these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks described in documents COTI has filed with the Toronto Stock Exchange and Ontario Securities Commission. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. 2
  • 3. 3 COTI-2 INTRODUCTION • COTI-2 is a small molecule with a novel mechanism of action, discovered by our CHEMSAS process – Originally thought to be an AKT modulator/inhibitor • It is a 3rd generation thiosemicarbazone engineered for low toxicity and easily synthesized in 3 steps • It demonstrates strong in vitro and in vivo efficacy • COTI-2 is effective in cancer cells/tumors with many common p53 mutations N N N H S N N N 3rd Generation Thiosemicarbazone
  • 4. 4 COTI-2 IC50 STRONGLY CORRELATED WITH p53 STATUS • TP53 is the most frequently mutated gene in human cancer with mutation frequencies ranging from 38% to 96%1 – Most frequent mutations occur in 6 “hotspot” codons2 • 23 cell line were evaluated for the relationship between their COTI-2 IC50 and p53 “hotspot” mutational status (amino acid residues 175, 248, and 273) – COTI-2’s efficacy was strongly associated with the presence of p53 “hotspot” mutations (Fisher exact, p = 0.0045) 1Freed-Pastor WA & Prives C (2012) Genes Dev. 26: 1268-1286. 2Yu X et al (2012) Cancer Cell, 21: 614-625.. LOW IC50 (< 250 nM) HIGH IC50 (≥ 250 nM) TOTAL Hotspot p53 Mutations (175, 248, 273) 13 0 13 WT p53 5* 5 10 TOTAL 18 5 23 Common p53 Gene Mutations COTI-2 Efficacy Associated with p53 Hotspot Mutations ~28% of human cancers * These cell lines also have mutations in p73 or the PI3K/AKT/mTOR pathway
  • 5. -10.00 -9.00 -8.00 -7.00 -6.00 -5.00 -4.00 -3.00 5 COTI-2 IC50 DISTRIBUTION IN HUMAN CANCER CELL LINES • COTI-2 IC50 distribution in various human cancer cell lines as illustrated by a waterfall chart shows 3 major groups of cell lines Normal Human WBCs MCF7 and NCI-H460: WT p53 + PIK3CA mutation U87MG: WT p53 + PTEN mutation NCI-H292: WT p53 + p73 mutation HCT116: WT p53 + PIK3CA mutation PANC-1: p53 (R273H) OVCAR-3 PK/PD xenograft p53 (R248G) GROUP 1 GROUP 2 GROUP 3 p53 = Wild-type Mutants = p53 Wild-type AND p73, PI3K, or PTEN Mutant p53 = Null Mutants p53 = Hotspot & Non-Hotspot Mutants
  • 6. 6 COTI-2 INDUCES A CONFORMATIONAL CHANGE IN MUTANT P53 • COTI-2 induces a ‘wild-type-like’ conformational change in mutant p53R175H in TOV- 112D ovarian cancer cell line • Data also suggests a mutant p53 conformational change also occurs in PANC-1 (p53R273H) pancreatic and OVCAR-3 (p53R248Q) ovarian cancer cell lines Experimental Design • Fluorescently labeled antibodies specific for wild-type & mutant p53 used to assess cells grown in the presence/absence of COTI-2 • PAB1620-stained cells show wild-type p53 and PAB240-stained cells show mutant p53 • Cy3 refers to the fluorescent signal emitted by the fluor attached to the antibodies • DAPI-staining indicates intact nuclei and provides the assurance that the cells are intact
  • 7. 7 COTI-2 HAS NO AFFECT ON P53 WILD-TYPE CONFORMATIONAL STATUS • COTI-2 has no affect on the wild-type p53 conformation as demonstrated by the H460 NSCLC cell line, which was used as a control Experimental Design • Fluorescently labeled antibodies specific for wild-type & mutant p53 used to assess cells grown in the presence/absence of COTI-2 • PAB1620-stained cells show wild-type p53 and PAB240-stained cells show mutant p53 • Cy3 refers to the fluorescent signal emitted by the fluor attached to the antibodies • DAPI-staining indicates intact nuclei and provides the assurance that the cells are intact
  • 8. 8 COTI-2 TARGETS P53 MUTANT PROTEIN • COTI-2 significantly reduces p53 mutant protein levels and significantly increases wild-type p53 protein levels in TOV-112D cells likely by inducing a conformational change • COTI-2 has no significant effect on p53 protein levels in the H460 cell line, which do not carry the mutant p53 protein • (*) Significant difference in p53 protein levels between COTI-2 treated and untreated cells (control) Mutant p53 Levels in the Presence/Absence of COTI-2 Wild-type p53 Levels in the Presence/Absence of COTI-2 0 20 40 60 80 100 120 TOV-112D H460 MeanFluorescenceIntensity (ArbitraryUnits) Cell Line Control COTI-2 * 0 20 40 60 80 100 TOV-112D H460 MeanFluorescenceIntensity (ArbitraryUnits) Cell Line Control COTI-2 *
  • 9. 9 COTI-2 AFFECTS A WIDE RANGE OF P53 MUTATIONS • COTI-2 inhibited a wide range of p53 mutations at concentrations  1.0 M – Fifteen p53 mutations were inhibited by COTI-2 (shown below in red) – The p53 mutations correspond to those most frequently occurring in various human cancers Experimental Design • HCT116 p53 (-/-) constructs were transfected with plasmids bearing various p53 mutant genes • Each transfectant was exposed to 1.0 M of COTI-2 for 72 hrs and viability assessed • The cell viability was determined using the CellTiter-Blue® Assay Unlike other p53 targeted drugs in development COTI-2 targets a wider range of p53 mutations N C S G C H L S C R W G Q C G S R Y V D A L P W L H P S F R175 C275R273R248G245Y220
  • 10. 10 COTI-2 REACTIVATES MUTANT P53 • COTI-2 reactivates the tumor suppressor properties of p53 as demonstrated by the induction of p21, which is a p53-dependent gene – COTI-2 induces p21 at 3 and 12 h post-exposure in both the HCT116 p53 (R175H) and (G245C) mutant constructs – No difference in p21 protein levels were observed in the HCT116 p53 (-/-) construct Experimental Design • Cells were incubated with/without COTI-2 and protein extractions performed at 2 and 12 h post-incubation • Protein levels were detected via western blots using p53, p21, and Erk2 specific antibodies 1 2 3 4 HCT116 p53 (R175H) HCT116 p53 (G245C)HCT116 p53 (-/-) 3h - + 12h - + 1 2 3 4 p53 p21 Erk2 COTI-2 3h - + 12h - + 3h - + 12h - + 1 2 3 4
  • 11. COTI-2 REACTIVATES MUTANT P53 THROUGH ZINC CHELATION • 8 genes involved in metal ion chelation up- regulated by COTI-2 (p<0.01) • Iron chelation unlikely to be significant effect • Pre-treatment of p53 mutant cell lines with TPEN markedly reduces COTI-2 effectiveness • COTI-2 increases intracellular zinc concentrations • Experiments are ongoing to better understand the role of zinc in COTI-2 effectiveness 11
  • 12. 12 CONFIRMATION OF P53-DEPENDENT MOA • Gordon Mills, MD., PhD., Chair of the Department of Systems Biology and the Co- Director of the Khalifa Institute for Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center in Houston, Texas conducted a number of cell-based experiments to further elucidate the activity of COTI-2 on various p53 mutations • Dr. Mills’ research confirmed – COTI-2 is most active in mutant p53 tumors – COTI-2’s activity in many specific p53 mutations is striking – COTI-2’s activity can be augmented by the presence of mutations in the AKT signaling pathway – Results of in vitro/in vivo studies in combination with the potential MOA warrant further clinical development “These results are encouraging given the central importance of p53 gene mutations in many cancers” Dr. Gordon Mills, MD Anderson Cancer Center
  • 13. 13 COTI-2 INDUCED NO SIGNIFICANT RESISTANCE • COTI-2 induced no significant resistance through 5 generations in both cell lines • Both Cisplatin and Placlitaxel induce significant increases in IC50 after first generation of selection compared with COTI-2 • COTI-2 induced a statistically significant decrease in IC50’s (i.e., Collateral Sensitivity) 0 0.5 1 1.5 2 2.5 3 Parental cells Round1 selection Round2 selection Round3 selection Round4 selection COTI-2 COTI-219 Cisplatin Paclitaxel 0 1 2 3 4 5 6 7 8 Parental cells Round1 selection Round2 selection Round3 selection Round4 selection COTI-2 COTI-219 Cisplatin Paclitaxel IC50Ratio DMS153 SCLC SHP77 SCLC IC50Ratio
  • 14. 14 COTI-2 PRODUCED SIGNIFICANT TGI AS A SINGLE AGENT • COTI-2 administered PO produced a significant tumor growth inhibition as a single agent in the OVCAR-3 ovarian cancer tumor model Experimental Design • OVCAR3 human tumor cells inoculated subcutaneously in the right and left flanks of female athymic mice (NIH III nu/nu), allowed to grow up to 75 to 100 mm3 • Groups of 12 mice each were dosed PO with COTI-2 in phosphate citrate buffer (75 or 100 mg/kg) with a schedule of 5X per week until study end • Tumor volumes were graphed as means (SE) and significant difference between groups was determined using Student’s T- test (p<0.05) • (*) Tumors significantly reduced by COTI-2 in all treatment groups relative to vehicle control 0 50 100 150 200 250 0 5 9 16 23 30 37 44 51 61 TumorVolume(mm3) Study Day Group 4 = Vehicle PO Group 5 = COTI-2 75mg/kg PO Group 6 = COTI-2 100mg/kg PO Effect of Treatment on Tumor Volume * * * * * * * * * * * *
  • 15. 15 SUMMARY • COTI-2 is a small molecule with a novel mechanism of action, discovered by our CHEMSAS process • MOA – COTI-2 appears to restore wild-type like functional activity to a wide range of p53 mutants through zinc chelation • In vitro efficacy – COTI-2 demonstrates nanomolar activity in multiple human cancer cell lines – COTI-2 did not induce cross-resistance compared to cisplatin and paclitaxel • In vivo efficacy – When administered PO, COTI-2 induced significant tumor growth inhibition (85.5%) in an ovarian tumor xenograft model without any overt toxicity in mice • Clinical development strategy – IND filing is planned for mid-2014 – Gynecological (ovarian, endometrial, and cervical) cancer patients failing 1st line therapy • FDA Orphan status granted June, 2014 “for the treatment of ovarian cancer”
  • 16. 16 COTI-2 NEGATIVELY MODULATES THE PI3K/AKT/MTOR PATHWAY 1Hennessy BT et al (2005) Nature Rev Drug Discov, 4: 988-1004. • This pathway has been implicated in cancer and is involved in cell proliferation, survival, motility and morphology1 • COTI-2 negatively modulates the PI3K/AKT/mTOR pathway – COTI-2 directly inhibits PI3K via the upregulation of PIK3IP1 – Increased/restored p53 function stimulates PTEN activity – Increased/restored p53 function leads to AKT protein degradation PI3K AKT MDM2 p53 FOXO1 BAD GSK3B mTOR S6KCASP-9 RTK Apoptosis Cell cycle regulation DNA repair Apoptosis Cell cycle regulation Growth Translation PIK3IP1 PTEN COTI-2 Upregulates PIK3IP1 Study # COTI-07-101
  • 17. Follow @CriticalOutcome on Twitter COTI-2 | Reactivating Mutant P53